Gilead takes another big swing at expanding beyond HIV
吉利德科学公司再度大举进军HIV以外领域

Gilead Sciences has dedicated around $11 billion so far this year to three acquisitions meant to bolster its pipelines in cancer and immunology. The pharma company, once criticized for making bad deals, hopes it can succeed this time in substantially diversifying from HIV.
吉利德科学公司今年迄今已投入约110亿美元用于三笔收购，旨在加强其肿瘤和免疫学管线。这家曾因糟糕交易而受批评的制药公司希望这一次能成功，实现从HIV领域的实质性多元化。